Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease
Study sponsor: Lakefront Biotherapeutics NV · LKFT
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-11-11Actual
Enrollment · participants1372Actual
Source updated2023-12-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.